LONDON: Diabetes's global epidemic is increasing the demand for insulin demand, but tens of millions does not have to get injections unless it is dramatic to improve access and accessibility, a new study ended Wednesday (Nov. 21)
Diabetes – blindness, kidney failure, heart problems, neuropathic pain and amputation – nowadays only affects 9% of adults worldwide, from the 1980's.
Most have a type 2 diabetes, with obesity and lack of exercise, and cases are developing rapidly in developing countries because people take lives in the West and the city.
The researchers said that the amount of insulin needed to treat Diabetes 2 effectively will increase in 20 percent over the next twelve years, but insulin would be half of the 79 million-day diabetic patients predicted in 2030.
The biggest mistake in Africa, the director of Sanjay Basu, Stanford University, should estimate the amount of supplies they need to spend seven times in order to treat the stage of insulin in patients who endanger their blood sugar levels.
"These estimates suggest that access to current insulin is very scarce due to the planned needs, especially in Africa and Asia," said Basu.
"In order to ensure the access to universal medication against diabetes, UN commitment to treat non-communicable diseases and universal insulin are scarce and difficult to access."
The global supply of insulin consists of three companies: Novo Nordisk, Sanofi and Eli Lilly, who have programs to improve their access to their products.
Insulin, however, remains expensive and prices are available in particular in poor countries, where heavy supply chains and large ups and downs often make salespeople overwhelming.
Overall, Basu and colleagues have estimated that using global insulin would rise from 634 million to 1,000 units by 2030 to 526 million in 2018.
The research published in Lancet Diabetes & Endocrinology and the prevalence of Diabetes Federation International Diabetes funded by Helmsley Charitable Trust.
The doctor at the McMaster University of Canada, Hertzel Gerstein, wrote an additional comment, which was important for calculating and guaranteeing insulin supplies, but because the outlook was based on a mathematical model, they should be treated wisely.
(Reporting to Ben Hirschler; Editing by Adrian Croft)